سعر دوسيتاكسيل ساندوز 80مجم/8مل مركز للتسريب الوريدي فيال 2025

Docetaxel sandoz 80mg/8ml conc. for i.v. inf. vial — docetaxel concentrate for IV infusion (Sandoz).

• Locally advanced or metastatic breast cancer after chemotherapy failure; adjuvant with doxorubicin+cyclophosphamide for operable node-positive BC (US Docetaxel).Population: Adults per US labelDailyMed / FDA
• NSCLC (mono after platinum failure; with cisplatin if chemo-naive unresectable); metastatic CRPC with prednisone; advanced gastric adenocarcinoma with cisplatin+fluorouracil; induction for locally advanced SCCHN with cisplatin+fluorouracil (US Docetaxel).Population: Adults per US labelDailyMed / FDA

• Most common across indications: infections, neutropenia/anemia/febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea/diarrhea/vomiting, mucositis, alopecia, skin reactions, myalgia (US Docetaxel).International label, same formulation · DailyMed / FDA

• Neutrophil count <1500 cells/mm³ (US Docetaxel).International label, same formulation · DailyMed / FDA
• History of severe hypersensitivity to docetaxel or drugs formulated with polysorbate 80 (US Docetaxel).International label, same formulation · DailyMed / FDA

• Boxed warning: toxic deaths (esp. abnormal LFTs / higher doses / NSCLC prior platinum at 100 mg/m²), hepatotoxicity, neutropenia, severe hypersensitivity including fatal anaphylaxis, severe fluid retention despite dexamethasone (US Docetaxel).International label, same formulation · DailyMed / FDA
• Embryo-fetal toxicity; advise effective contraception (females 2 months, males 4 months after last dose); do not breastfeed during and for 1 week after last dose (US Docetaxel).International label, same formulation · DailyMed / FDA

• Strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir)MajorMay increase docetaxel exposure; avoid; consider ~50% dose reduction if unavoidable (US Docetaxel). Management: Avoid coadministration when possible; monitor toxicity.DailyMed / FDA

• Can cause fetal harm based on animal data and mechanism; limited human data; advise of potential risk (US Docetaxel PLLR).International label, same formulation · DailyMed / FDA
• Advise women not to breastfeed during treatment and for 1 week after the last dose (US Docetaxel).International label, same formulation · DailyMed / FDA

• Docetaxel: Binds beta-tubulin, promotes microtubule assembly and stabilizes microtubules, inhibiting mitosis.